Summary and Discussion Points for Pharmacokinetic (Category2) & Clinical Abuse Potential Studies (Category3):
Interpretation of Human Abuse Potential Studies and Clinically Important Responses to ADFs:
Structuring the Submission of Abuse Deterrence Data and Formulating the ADF Label:
PK/PD analysis in assessment of abuse deterrence: